VRNA241220C20000
- 22.20
- +0.09+0.41%
Verona Pharma Newsroom
Five Reasons Why UBS Is Overweight the UK
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Down 1.5% for Week
Have Verona Pharma Insiders Been Selling Stock?
Jefferies Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $50
Verona Pharma Announces December 2024 Investor Conference Participation
Verona Pharma Plc's (NASDAQ:VRNA) Path To Profitability
Druckenmiller made significant adjustments in the third quarter: opened positions in Bank of America and Broadcom, continued to increase holdings in the top position Natera.
Natera's position significantly increased by 80.61% compared to the previous quarter. Druckenmiller also established new positions in Broadcom, banks, and pharmaceutical stocks, while completely liquidating News Corp and telecom company Liberty Global, and reducing shareholding in microsoft.
Druckenmiller's Duquesne Closes Some Media Holdings, Loads Into Regional Banks, Among Q3 Trades
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating
Form 144 | Verona Pharma(VRNA.US) Officer Proposes to Sell 4.82 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $Verona Pharma(VRNA.US)$ Officer MARK HAHN intends to sell 125K shares of its common stock on Nov 11, with a total market value of approximately $4.82 million.
Form 144 | Verona Pharma(VRNA.US) Director Proposes to Sell 4.82 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $Verona Pharma(VRNA.US)$ Director DAVID ZACCARDELLI intends to sell 125K shares of its common stock on Nov 11, with a total market value of approximately $4.82 million.
European Equities Traded in the US as American Depositary Rise Thursday
Verona Pharma Insider Sold Shares Worth $618,658, According to a Recent SEC Filing
Wells Fargo Maintains Overweight on Verona Pharma, Raises Price Target to $64
Verona Pharma Is Maintained at Buy by Canaccord Genuity
A Quick Look at Today's Ratings for Verona Pharma(VRNA.US), With a Forecast Between $42 to $64
Express News | Verona Pharma PLC : H.c. Wainwright Raises Target Price to $42 From $36
Verona Pharma Receives Buy Rating Amid Strong Financial Performance and Growth Prospects
BTIG Remains a Buy on Verona Pharma (VRNA)
Verona Pharma (NASDAQ:VRNA) Shareholder Returns Have Been Incredible, Earning 724% in 5 Years